جست‌وجوی استاد و پژوهشگر

Shalomeev Vadim Anatoliyovychمشاهده پروفایل

استاد

• Materials Science
• Metallurgy
• Magnesium Alloys
• +۳ مورد دیگر

Vadim Anatoliyovych Shalomeev is Doctor of Technical Sciences and Professor who serves as Vice-Rector for Research at Zaporizhzhia Polytechnic University. With a career spanning since 1984, he specializes in magnesium alloys, particularly their development for both aircraft engine manufacturing and medical applications (specifically biodegradable implants for osteosynthesis). Professor Shalomeev's research focuses on the development and research of magnesium alloys for aircraft engine manufacturing and medicine. His work bridges materials science, metallurgy, and biomedical engineering, with particular emphasis on improving the properties of magnesium alloys through various alloying techniques, processing methods, and surface treatments. His research has significant applications in demanding fields like aerospace engineering and medical implant technology. Analysis of his recent publications reveals a strong focus on biodegradable magnesium alloys for medical implants, with particular attention to alloying elements (silver, gold, noble metals), microstructure characterization, corrosion resistance, and mechanical properties. His work also extends to steel alloys and resource-saving technologies in metallurgy. Professor Shalomeev has contributed to numerous patents related to magnesium alloys and has published extensively in journals covering materials science, metallurgy, and biomedical engineering. His research has practical applications in both the medical field (osteosynthesis implants) and industrial sectors (aerospace, mining). In addition to his research responsibilities, Professor Shalomeev teaches Descriptive geometry, engineering and computer graphics, contributing to the education of future engineers at Zaporizhzhia Polytechnic University.

Allen Holderمشاهده پروفایل

استاد

• Optimization
• Mathematical Programming
• Computational Biology
• +۷ مورد دیگر

Allen Holder is a Professor of Mathematics at Rose-Hulman Institute of Technology with research affiliations at Indiana University School of Medicine, Cancer Therapy Research Center (San Antonio), and Huntsman Cancer Center (Salt Lake City). His work bridges optimization theory with real-world applications in medicine, biology, and industrial systems. Education PhD, University of Colorado-Denver, 1998 MS, University of Southern Mississippi, 1993 BS, University of Southern Mississippi, 1990 Dr. Holder specializes in mathematical programming applied to computational biology (protein structure alignment, metabolic networks), medical physics (radiotherapy optimization), and industrial engineering (foundry scheduling). His cross-disciplinary approach has driven the establishment of Rose-Hulman's biomathematics major and enabled breakthroughs like a 1000x faster protein analysis algorithm developed with Dr. Yosi Shibberu. His 2011-2015 publications reveal a consistent pattern of applying operations research to high-impact biological and medical challenges, particularly in genome-scale modeling and radiation oncology optimization, while maintaining industrial applications in scheduling. Scientific Recognition Board of Trustees Outstanding Scholar (2015) 4-time Blue Key Favorite Professor (2001,2003,2005,2006) INFORMS Moving Spirit Award (2003) 2-time Alpha Lambda Delta Professor of the Month (2000,2003) Dr. Holder has mentored nearly 50 undergraduate researchers and serves as editor for multiple publications. His collaborative grants span medical centers and industrial partners, focusing on translating optimization theory into clinical and manufacturing solutions. He leads cross-institutional teams including Rose-Hulman biology/chemistry faculty, Indiana University medical researchers, and cancer center specialists, driving translational projects from algorithm development to clinical implementation.

• Casting
• Foundry Engineering
• Materials Science
• +۳ مورد دیگر

Professor Zenon Ignaszak is a distinguished faculty member at Poznań University of Technology, working within the Faculty of Mechanical Engineering and the Institute of Materials Technology. With a career spanning over four decades since his doctoral dissertation in 1979, he has established himself as a leading expert in foundry engineering and casting technology. His research interests focus on computer simulation of casting processes, virtual prototyping in foundry applications, thermophysical properties of molding materials, and quality control in metal casting production. Professor Ignaszak has made significant contributions to understanding microstructure formation in aluminum alloys, graphite expansion phenomena in ductile iron, and moisture-related phenomena in sand molds. His publication record includes 59 journal articles, 28 book chapters, and 2 scientific monographs, with active research continuing through 2020. His most recent work examines database validation for jewelry casting design, cause-effect analysis for quality prediction, and open defect atlases for cast iron analysis. Professor Ignaszak has supervised four doctoral dissertations and collaborated extensively with researchers including Robert Sika, Jakub Hajkowski, Paweł Popielarski, and Piotr Mikołajczak. His work bridges theoretical modeling with practical industrial applications in the foundry sector. He has contributed to the field through two patented inventions: removable casting cores and systems for measuring mold cavity filling time/speed, demonstrating his commitment to practical innovation alongside theoretical research.

• Emerging Technologies
• Enabling Technologies
• General Purpose Technologies
• +۴ مورد دیگر

Dr. Ambarin Khan serves as a Lecturer at Salford Business School, University of Salford, where she leads the MSc Entrepreneurship and Innovation program. Her academic career spans multiple institutions including Coventry University, Alliance Manchester Business School, and Pakistani universities (Institute of Business Management and Institute of Business Administration), alongside significant industry experience. Her educational qualifications demonstrate deep expertise in technology management: Bachelors of Engineering (Electrical), 1991-1996 MBA in International Marketing, 1999-2001 MSc in Management of Science, Technology and Innovation, 2008-2009 PhD in Innovation Management and Policy, 2009-2016 Dr. Khan's research centers on emerging technologies within business ecosystems, specifically examining how entrepreneurial firms, incumbents, and intermediaries develop business models for breakthrough innovations. Her doctoral work on organic electronics directly informs her current role in the GM AI Foundry project, where she translates theoretical frameworks into practical AI adoption strategies for SMEs. As co-investigator for the GM AI Foundry (2020-2023), she developed workshops that enabled over 45 SMEs to implement AI solutions. Her teaching portfolio—including Entrepreneurial Business Simulation and Strategic Management—integrates this research-practice nexus, preparing students for technology-driven business challenges through hands-on learning experiences.

• Bioorthogonal Chemistry
• Glycobiology
• Chemical Biology
• +۶ مورد دیگر

Carolyn Ruth Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University's School of Humanities and Sciences, where she leads a pioneering research program at the interface of chemistry and biology. She is also an Investigator of the Howard Hughes Medical Institute and previously served as director of the Molecular Foundry at Lawrence Berkeley National Laboratory. Her groundbreaking work has established the field of bioorthogonal chemistry - developing chemical reactions that can selectively occur within living systems without disrupting normal biological processes. PhD in Chemistry from University of California, Berkeley Nobel Laureate in Chemistry Member of National Academy of Sciences Fellow of American Academy of Arts and Sciences Dr. Bertozzi's research focuses on the chemical biology of cell surface glycans and their roles in health and disease. She pioneered methods to study and manipulate glycans in living systems, coining the term 'bioorthogonal chemistry' for her revolutionary approach. Her recent work has centered on understanding how glycans interact with the immune system, particularly through Siglec receptors, creating a new field of 'glyco-immune checkpoints' with significant therapeutic implications. She has also developed lysosome-targeting chimeras (LYTACs) for targeted protein degradation, expanding the toolbox for therapeutic intervention. Analysis of her recent publications reveals a strong trend toward applying chemical biology to immunology and cancer therapy, with increasing focus on glyco-immune interactions, targeted protein degradation, and host-pathogen relationships. Her work consistently bridges fundamental chemical discovery with translational applications, maintaining leadership in both basic science and therapeutic development. Nobel Prize in Chemistry Wolf Prize in Chemistry Lemelson-MIT Prize Heineken Prize for Biochemistry and Biophysics American Chemical Society Award in Pure Chemistry Dr. Bertozzi has mentored numerous graduate students and postdoctoral fellows who have gone on to successful careers in academia and industry. Her lab has been continuously funded by major grants from the National Institutes of Health, National Science Foundation, and private foundations, supporting innovative research at the chemistry-biology interface. She has founded multiple biotechnology companies to translate her discoveries into clinical applications, particularly in cancer immunotherapy and targeted protein degradation. Her laboratory, known for its interdisciplinary approach, brings together chemists, biologists, and engineers to develop and apply novel chemical tools for biological discovery. Current research directions include refining bioorthogonal reactions for in vivo use, developing next-generation antibody-drug conjugates, and exploring how glycan modifications influence immune responses in cancer and infectious disease.